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Recommendation to Temporarily Suspend Usage of GlaxoSmithKline 
Rotarix (Rotavirus) Vaccine
Summary: The U.S. Food and Drug Administration (FDA) has learned that DNA from porcine circovirus 
type 1 (PCV1), a virus not known to cause disease in humans, is present in the Rotarix vaccine.All 
available evidence indicates that there has been no increased risk to patients who have received this 
vaccine.PCVI is not known to cause any disease in animals or humans; therefore, it has not been 
routinely tested for in vaccine development.Rotarix has been extensively studied, before and after 
approval, and found to have an excellent safety record (i.e., no unusual adverse events). However, FDA 
is recommending that healthcare practitioners temporarily suspend usage of the Rotarix vaccine for 
rotavirus immunization in the United Stateswhile the agency learns more about the detection of 
components of the virus found in the vaccine.
Background
FDA has learned that DNA from porcine circovirus type 1 (PCV1) is present in the Rotarix vaccine.This 
finding was reported to FDA by GlaxoSmithKline on March 15th, 2010, based on work originally performed 
by an academic research team using a novel technique to look for viruses.GlaxoSmithKline then 
conducted additional studies and confirmed that PCV1 DNA is present in the finished Rotarix vaccine, as 
well as in the cell bank and seed from which the vaccine is derived.This finding suggests that the PCV1 
DNA has likely been present since the early stages of the vaccine's development.
Rotavirus vaccines are given by mouth to young infants to prevent rotavirus disease, which can cause 
severe diarrhea and dehydration.Each year, rotavirus disease causes more than 500,000 deaths in 
infants globally, and more than 50,000 hospitalizations and several dozen deaths in the United 
States.There are two licensed rotavirus vaccines in the United States:RotaTeq (Merck) and Rotarix 
(GlaxoSmithKline).
Recommendations
While FDA is learning more about the situation, the agency is recommending that clinicians temporarily 
suspend the use of Rotarix.This recommendation applies to all lots of the Rotarix vaccine.RotaTeq 
vaccine is available for rotavirus immunization during this period. For children who have received one 
dose of Rotarix, CDC advises that clinicians complete the series with RotaTeq for the next two doses.
Since RotaTeq was licensed in 2006 and Rotarix in 2008, most children vaccinated in the United 
Statesreceived RotaTeq.The RotaTeq vaccine is made using a different process from the Rotarix 
vaccine.Preliminary studies by FDA on the RotaTeq vaccine have not shown the presence of PCV1 
DNA.FDA is working with Merck to confirm these results.
FDA is obtaining additional information about the presence of PCV1 DNA in Rotarix, including whether 
intact virus (as opposed to DNA components) is present.FDA is also investigating how the PCV1 DNA 
came to be present in the vaccine.
Within the next four to six weeks, FDA will convene an advisory committee to review the available data 
and make recommendations on the licensed rotavirus vaccines.FDA will also seek input on the use of 
new techniques for identifying viruses in vaccines.The agency anticipates that following the advisory 
committee meeting, based on expert input and additional review, FDA will make further recommendations 
on the use of the two licensed rotavirus vaccines in the United States.
The recommendations detailed above are for the United States, where there is less rotavirus disease and 
an alternative vaccine is available. Other countries may decide to continue vaccinating with Rotarix while 
more information becomes known.Available evidence suggests that the benefits of continued use of 
Rotarix in countries where rotavirus disease is common and severe far outweigh any potential risk from 
the vaccine.
Clinicians are requested to report any suspected adverse events following Rotarix vaccination to the 
Vaccine Adverse Event Reporting System (VAERS) via phone 800-822-7967 or on-line: 
http://vaers.hhs.gov.
For More Information:
FDA intends to provide frequent updates to patients, providers, and the general public as its 
understanding evolves.Additional information is available at: www.fda.gov.
